Compare Cytokinetics Inc (CYTK) vs Redwire Corporation (RDW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Redwire Corporation — how do they compare? Cytokinetics Inc trades at $62.02 (market cap $8.50B), while Redwire Corporation trades at $9.93 (market cap $2.56B). The key difference: Cytokinetics Inc is far larger — about 3.3× Redwire Corporation's market cap, and Redwire Corporation is more actively traded (14,037,053 versus 2,395,556). Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Redwire Corporation for 18 Days on average.
| CYTK | RDW | |
|---|---|---|
Market Cap | $8.50B | $2.56B |
Volume | 2,395,556 | 14,037,053 |
Sector | Health | Industrials |
52-Week High | $87.26 | $25.90 |
52-Week Low | $54.76 | $5.06 |
Typical Hold Time | 19 Days | 18 Days |
Enterprise Value | $8.60B | $2.09B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $61.12, down 0.37% on the day, with a bearish technical signal from moving averages but bullish momentum from oscillators. The company reported a net loss of -$784.96M on $88.04M revenue in 2025, with a negative net income margin of -1,321.12%. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy, including Phase 3 results and real-world study launches.
Despite heavy losses, strong analyst consensus (97.14% buy ratings) and a $112.50 price target reflect optimism for its heart failure pipeline. Key risks include sustained cash burn, competitive pressure from Bristol Myers Squibb's Camzyos, and the need for successful commercialization to justify its high P/S ratio of 112.42.
Redwire Corporation (RDW) trades at $10.24, down 3.58% with bearish technical signals despite 80% analyst buy ratings. The company shows strong revenue growth (89.6% YoY in Q2 2026) but faces profitability challenges with negative net margins (-57.26%) and consecutive earnings misses. Recent Space Force contract wins and partnerships highlight growth potential in the expanding space infrastructure market, though cash flow remains negative from operations.
The stock presents a high-risk growth opportunity with significant upside to the $14.88 consensus target if execution improves, but persistent losses and dependence on SpaceX's Starship timeline create substantial volatility. Investors must weigh strong institutional support against fundamental weaknesses in a speculative sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Redwire Corporation
Redwire Corporation is a pure-play space infrastructure company that provides a wide range of advanced solutions for the next generation of space exploration and utilization. The company's capabilities span critical space technology, including on-orbit servicing, satellite components, space robotics, and digital engineering. Redwire's products and services are used by civil, commercial, and national security customers to enable missions from low Earth orbit to deep space.
Read more on RDW →
